2013 Archived Content
Over the past few years, widespread efforts canvassing academia, government and industry have set out to interrogate and map epigenomic environments during the onset and progression of various complex diseases. The suite of epigenetic modifications, collectively forming a dynamic epigenetic code, has long been known to operate as the manager of the genomic blueprint, wielding cell-dependent control over gene expression at discrete times throughout development. More recently, fueled in part by the application of high-throughput sequencing technologies, our understanding of the disease epigenome has expanded, with the inclusion of numerous gene mutations and epimutations directly involved in producing aberrant gene expression. Importantly, these findings form inextricable causal links between our underlying genome, a dynamic epigenome, and the functional (disease) consequences stemming from both. Cambridge Healthtech Institute is proud to announce The Clinical Epigenome Conference (TCEC), highlighting the interplay between disease-genome-epigenome, while exploring the profound opportunities of applying epigenomic analysis for diagnostics and personalized treatment.
Whole Genome Phasing and Analysis of a Personal Methylome
Michael Snyder, Ph.D., Professor and Chair, Genetics; Director, Stanford Center for Genomics and Personalized Medicine, Stanford University
Spontaneous and Therapy Induced Evolution of Tumor Genomes and Epigenomes
Joseph Costello, Ph.D., Professor in Residence, Department of Neurological Surgery; Director, Epigenetics Division, Cell Cycling and Signaling Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco